Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.
Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N. Ploquin A, et al. Among authors: twelves c. Br J Cancer. 2012 Sep 25;107(7):1025-30. doi: 10.1038/bjc.2012.371. Epub 2012 Aug 21. Br J Cancer. 2012. PMID: 22910320 Free PMC article.
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.
Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, Campone MM, Twelves CC, Raymond E, Hegi ME, Lacombe D, van den Bent MJ. Gorlia T, et al. Among authors: twelves cc. Eur J Cancer. 2012 May;48(8):1176-84. doi: 10.1016/j.ejca.2012.02.004. Epub 2012 Mar 28. Eur J Cancer. 2012. PMID: 22464345
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C. Benson C, et al. Among authors: twelves c. Br J Cancer. 2007 Jan 15;96(1):29-37. doi: 10.1038/sj.bjc.6603509. Epub 2006 Dec 19. Br J Cancer. 2007. PMID: 17179992 Free PMC article. Clinical Trial.
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
Clamp AR, Schöffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, Chick J, Jayson GC; EORTC New Drug Development Group. Clamp AR, et al. Among authors: twelves c. Cancer Chemother Pharmacol. 2008 Apr;61(4):579-85. doi: 10.1007/s00280-007-0509-5. Epub 2007 May 23. Cancer Chemother Pharmacol. 2008. PMID: 17520255 Clinical Trial.
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J. Vasey PA, et al. Among authors: twelves c. Clin Cancer Res. 1999 Jan;5(1):83-94. Clin Cancer Res. 1999. PMID: 9918206 Clinical Trial.
307 results